BY002 / Beyang Therapeutics - LARVOL DELTA

A single-center, open-label IIT clinical study evaluating the safety, pharmacokinetics, and efficacy of the Menin inhibitor BY002 in patients with relapsed/refractory acute leukemia (ChiCTR) - P1 | N=24 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • KMT2A • NPM1

Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: First Affiliated Hospital of Zhejiang University

First-in-human • New P1 trial

BY002 IIT Study in R/R Acute Leukemia (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University | Trial completion date: Dec 2026 ➔ Jul 2027 | Initiation date: Nov 2025 ➔ Mar 2026 | Trial primary completion date: Jun 2026 ➔ Mar 2027

First-in-human • Trial completion date • Trial initiation date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • KMT2A • NPM1